tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Allogene Therapeutics downgraded to Neutral from Overweight at JPMorgan

JPMorgan analyst Brian Cheng downgraded Allogene Therapeutics (ALLO) to Neutral from Overweight with no price target after the company reported a fatal event in cemacabtagene ansegedleucel, or cema-cel’s, pivotal front-line consolidation large B-cell lymphoma ALPHA 3 study. The announcement “came as a surprise,” says the analyst, who finds it “difficult to remain confident in cema-cel” following a recent series of setbacks. After updating the firm’s model to reflect today’s announcement, the firm is lowering penetration assumptions and probability of success for cema-cel in first-line consolidation LBCL, the analyst noted.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1